Floatz logo

PANITUMUMAB

Gestational Diabetes

University of North Carolina, Chapel Hillmonoclonal_antibodyN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Gestational Diabetes cohort.

Asset / SponsorPhaseRating
Metformin
Ain Shams University
Phase 4A
Letrozole
Ain Shams University
Phase 4BBB
GLUCOSE, ANHYDROUS
Siirt University
Phase 3B
INSULIN SUSP ISOPHANE RECOMBINANT HUMAN
University Hospital, Strasbourg, France
Phase 2CCC
Folic Acid
University of Messina
N/AD

Same molecule, other indications

PANITUMUMAB is also rated in:

neoplasmDormant
BBB
Indicative ·
73 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
70 / 100
View asset →
malignant pancreatic neoplasmDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →